AFT Pharmaceuticals (ASX:AFP) Carries Record FY26 Earnings Into a Broader Pipeline Test

Aditi Sarkar

03 August 2026 01:57 PM AEST

AFT Pharmaceuticals (ASX:AFP) Carries Record FY26 Earnings Into a Broader Pipeline Test

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

FY26 Revenue increased approximately 22% to NZD 254.7 million.
Operating profit rose about 39% to NZD 24.4 million and NPAT increased approximately 24% to NZD 14.1 million.
Management guided to more than NZD 300 million of FY27 revenue and NZD 28 million to NZD 32 million of operating profit.
The US FDA granted tentative approval for Scomara, although orphan-drug exclusivity delays a US launch until around March 2029.

AFT Pharmaceuticals (ASX:AFP) enters FY27 with record Earnings , an expanding Maxigesic Franchise and several pipeline programmes. Unlike many smaller pharmaceutical companies, AFT already generates profit from established products across multiple markets. July’s tentative United States approval for Scomara added regulatory validation, but commercial exclusivity blocks a near-term US launch. The next phase depends on delivering guidance, expanding American analgesic sales and funding development without allowing higher Debt or pipeline costs to weaken the core Business .

Company Overview

AFT is a trans-Tasman specialty pharmaceutical company listed in Australia and New Zealand. Its principal franchise is Maxigesic, a patented combination of paracetamol and ibuprofen sold in oral and intravenous forms. The company sells directly in Australia, New Zealand and parts of Asia and licenses products in more than 50 countries. Its development portfolio includes Scomara, intravenous iron and additional treatments.

Latest Update

For the year ended 31 March 2026, revenue increased approximately 22% to NZD 254.7 million. Operating profit rose around 39% to NZD 24.4 million, while NPAT increased about 24% to NZD 14.1 million. The Dividend rose approximately 39%. Management guided to more than NZD 300 million in FY27 revenue and operating profit between NZD 28 million and NZD 32 million. Gross Margin eased slightly to 42.7%, and net debt increased to approximately NZD 38.6 million.

Operations and Strategic Direction

Maxigesic combines paracetamol and ibuprofen and is positioned as an opioid-sparing pain treatment. The intravenous product, marketed as Combogesic in the United States, received full FDA approval in 2023. A 2026 distribution agreement with Cost Plus Drugs provides national US access. On 21 July 2026, the FDA granted tentative approval to Scomara, a once-daily rapamycin cream for facial angiofibromas associated with tuberous sclerosis complex.

Financial and Market Snapshot

Tentative approval confirms the application’s quality, safety and efficacy position, but another product’s orphan-drug exclusivity prevents a US Scomara launch until approximately March 2029. Ex-US markets are not affected by that restriction. AFT’s Market Value was around AUD 414 million in the source article. The group combines commercial earnings with pipeline optionality, although higher debt and development expenditure increase the need for disciplined cash generation and product prioritisation.

Broader Context

Debt management becomes more important as AFT funds launches and late-stage development. Cash conversion offers another practical measure of the quality of reported earnings. Customer Demand can change quickly when economic conditions and competitive behaviour shift. Capital allocation remains relevant because every expansion decision carries an Opportunity cost . Management commentary will be weighed against measurable revenue, margin and cash-flow outcomes. Longer-term progress depends on maintaining service quality while controlling the cost base. However, concentration in particular products, regions or customers can increase earnings sensitivity.

What May Be Watched Next

Readers may watch US sales of Maxigesic IV and Combogesic, first-half FY27 results expected around November and progress against revenue and operating-profit guidance. The planned Phase 3 intravenous iron trial in the second half of 2026 is another milestone. Ex-US Scomara commercialisation, gross margin, debt and partner-led product launches may also influence performance.

Key Risks

US commercial uptake may develop more slowly than expected, while Scomara cannot enter that market until exclusivity expires. Clinical Trials can Fail , require more capital or experience regulatory delay. Net debt increased materially during FY26, reducing financial flexibility. Currency, product mix, input costs and partner execution may affect margins. AFT also relies substantially on Maxigesic, leaving earnings exposed to competition, Patent issues or weaker demand.

FAQs

Q: What is AFT Pharmaceuticals’ principal product franchise?

A:AFT’s principal franchise is Maxigesic, a combination paracetamol-and-ibuprofen pain treatment sold in several forms.

Q: What were AFT’s main FY26 results?

A:Revenue reached NZD 254.7 million, operating profit was NZD 24.4 million and NPAT increased to NZD 14.1 million.

Q: What does tentative FDA approval mean for Scomara?

A:The application met approval requirements, but US commercial launch is delayed by another product’s exclusivity until around March 2029.

Q: What may be watched next for AFT Pharmaceuticals?

A:FY27 guidance, US analgesic sales, the intravenous iron trial, Scomara markets, margins, cash flow and debt may remain important.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.